Rihmer Z, Arató M, György S, Révai K, Demeter E
Pharmacopsychiatry. 1985 Sep;18(5):306-8. doi: 10.1055/s-2007-1017386.
The dexamethasone suppression test (DST) and response to two different antidepressant drugs (maprotiline as a specific noradrenergic, and amitriptyline as a predominantly serotoninergic drug) were investigated in 44 endogenously depressed female inpatients. The more anxious and/or agitated patients were mostly treated with amtiriptyline, the non-anxious and retarded patients with maprotiline. It was found that among maprotiline responders (N = 15) there were significantly more abnormal DSTs and postdexamethasone serum cortisol levels were significantly higher than among amitriptyline responders (N = 16). On the other hand, DST abnormalities among amitriptyline non-responders (N = 10) were similar to those among maprotiline responders. The results confirm earlier reports by Brown et al. (1980), Ettigi et al. (1983) and Fraser (1983) and indicate that abnormal DST may identify the "noradrenergic" subtype of endogenous depression and that the DST represents a good way of selecting a specific antidepressant drug for the treatment of endogenously depressed patients.
对44名内因性抑郁的女性住院患者进行了地塞米松抑制试验（DST）以及对两种不同抗抑郁药物（马普替林作为一种特异性去甲肾上腺素能药物，阿米替林作为一种主要的5-羟色胺能药物）反应的研究。焦虑和/或烦躁的患者大多使用阿米替林治疗，非焦虑和迟滞的患者使用马普替林治疗。结果发现，在马普替林治疗有效的患者（N = 15）中，DST异常的情况明显更多，且地塞米松给药后的血清皮质醇水平显著高于阿米替林治疗有效的患者（N = 16）。另一方面，阿米替林治疗无效的患者（N = 10）中的DST异常情况与马普替林治疗有效的患者相似。这些结果证实了Brown等人（1980年）、Ettigi等人（1983年）和Fraser（1983年）早期的报告，并表明DST异常可能识别出内因性抑郁的“去甲肾上腺素能”亚型，且DST是为内因性抑郁患者选择特定抗抑郁药物的一种好方法。
